Pardes Biosciences
- Company typePrivate
- Founded2020
- HeadquartersCarlsbad, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Pardes Biosciences firmographics
Firmographics- Name
- Pardes Biosciences
- Website
- https://pardesbio.com
- Company type
- Private
- Founded year
- 2020
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Pardes Biosciences industry classification
Industry- Product category
- Antiviral Therapeutics (Biotechnology)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where Pardes Biosciences is headquartered
LocationHeadquarters
- HQ city
- Carlsbad
- HQ country
- United States
- HQ region
- North America
Markets served
Pardes Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Pardes Biosciences product offering
Product offeringCore offering
Pardes Biosciences was a clinical-stage biotechnology company developing direct-acting antiviral (DAA) therapeutics for the treatment of coronavirus infections. Its primary focus was on oral protease inhibitors targeting SARS-CoV-2. Following delisting from NASDAQ and the domain being parked, the company appears to no longer be operational.
Differentiator
Problem solved
Functional benefit
Products and services
- PBI-0451 (oral SARS-CoV-2 protease inhibitor program) A clinical-stage, oral direct-acting antiviral therapeutic candidate being developed for the treatment of COVID-19 / SARS-CoV-2 infection, targeting the viral main protease. Intended as a small-molecule treatment for patients with coronavirus infection.
Companies that use Pardes Biosciences
Customer profileIdeal customer profiles1 record
Pardes Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Pardes Biosciences competitors and assessment
Company assessmentDirect peers
- Atea Pharmaceuticals: Atea developed AT-527, an oral direct-acting antiviral for COVID-19, making it the closest comparable to Pardes' lead program. Atea similarly struggled as the acute COVID market contracted, illustrating the same single-asset, late-mover risk that materialized for Pardes.
- Shionogi: Shionogi developed ensitrelvir (Xocova), an oral SARS-CoV-2 protease inhibitor approved in Japan, directly comparable to Pardes' oral antiviral approach. Both target the same viral protease mechanism with the same oral, outpatient positioning.
- Cocrystal Pharma: Cocrystal Pharma develops oral broad-spectrum antivirals, including COVID-19 candidates using a structure-based platform. Comparable as a small, publicly traded antiviral developer with a similar capital profile and direct-acting antiviral focus.
- Enanta Pharmaceuticals: Enanta pursued SARS-CoV-2 protease inhibitor candidates as an extension of its hepatitis C virus protease chemistry expertise. Comparable as a small-cap antiviral R&D company with similar mechanism-of-action focus and competitive dynamics.
Broad incumbents
- Pfizer: Pfizer developed and commercialized Paxlovid (nirmatrelvir/ritonavir), which dominated the oral COVID antiviral market and displaced late-arriving entrants like Pardes. Relevant as the dominant incumbent defining the competitive ceiling.
- Merck & Co. Merck developed molnupinavir (Lagevrio), another first-wave oral COVID antiviral that, alongside Paxlovid, captured the bulk of global demand and constrained follow-on programs. Comparable as a broad incumbent shaping the addressable market.
Emerging players
- Vir Biotechnology: Vir pursued COVID-19 therapeutics (initially monoclonal antibodies, later expanding to small-molecule antivirals via collaborations with Alnylam and Brii Biosciences). Comparable as a smaller-cap infectious disease specialist with overlapping pandemic-response themes and a similar trajectory profile.
- RedHill Biopharma: RedHill commercialized opaganib for COVID-19 in select markets and operates as a smaller infectious-disease biotech. Comparable as a sub-scale competitor pursuing COVID antiviral or anti-inflammatory indications.
Market position
Customer concentration
Pardes Biosciences social profiles
Digital presencePardes Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pardes Biosciences leadership team
Management profileNumber of profiles
Profiles2 records
Pardes Biosciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pardes Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pardes Biosciences
What does Pardes Biosciences do?
Pardes Biosciences was a clinical-stage biotechnology company developing direct-acting antiviral (DAA) therapeutics for the treatment of coronavirus infections. Its primary focus was on oral protease inhibitors targeting SARS-CoV-2. Following delisting from NASDAQ and the domain being parked, the company appears to no longer be operational.
When was Pardes Biosciences founded?
Pardes Biosciences was founded in 2020. It employs 11 to 50 people.
Where is Pardes Biosciences based?
Pardes Biosciences is headquartered in Carlsbad, United States, in the North America region.
Who are Pardes Biosciences's main competitors?
Direct peers on record are Atea Pharmaceuticals, Shionogi, Cocrystal Pharma and Enanta Pharmaceuticals. Broad incumbents are Pfizer and Merck & Co.. Emerging players are Vir Biotechnology and RedHill Biopharma.
Does Pardes Biosciences have an API?
No public API is recorded for Pardes Biosciences.
What industry is Pardes Biosciences in?
Pardes Biosciences's product category is Antiviral Therapeutics (Biotechnology). Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.